BrainStorm Gets Hopeful Window into NurOwn's Effect on Progressive MS
Progressive Multiple Sclerosis (MS)
BrainStorm Cell Therapeutics announced positive data from a Phase II safety and efficacy study of NurOwn in progressive multiple sclerosis on Oct. 14.
October 14, 2021 /by Andrew Humphreys
https://www.pharmalive.com/wp-content/uploads/2021/10/BrainStorm-Gets-Hopeful-Window-into-NurOwns-Effect-on-Progressive-MS-BioSpace-10-14-21.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2021-10-14 12:17:482021-10-14 12:19:04BrainStorm Gets Hopeful Window into NurOwn's Effect on Progressive MS
BrainStorm Trial Shows Promising Top-Line Results for Progressive MS
Clinical Trials, Neurodegenerative Diseases, Progressive Multiple Sclerosis (MS), R&D, Stem Cell Therapy, Topline Data
BrainStorm Cell Therapeutics, one of the leading developers of adult stem cell therapies that mainly focuses on adult neurodegenerative diseases, reported that the company's 28-week-long Phase II clinical trial for progressive multiple sclerosis (MS) came to a close.
March 24, 2021 /by Andrew Humphreys
https://www.pharmalive.com/wp-content/uploads/2021/03/BrainStorm-Trial-Shows-Promising-Top-Line-Results-for-Progressive-Multiple-Sclerosis-BioSpace-3-24-21.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2021-03-24 10:19:332021-03-24 10:22:15BrainStorm Trial Shows Promising Top-Line Results for Progressive MS
MediciNova's Ibudilast Reduces Retinal Thinning in MS Trial Subjects
Cancer Chemotherapy and Pharmacology, Chemotherapy-Induced Peripheral Neuropathy (CIPN), Clinical Data, Clinical Trials, Cytokines, Multiple Sclerosis, Multiple Sclerosis Journal, Peripheral Neuropathy, Progressive Multiple Sclerosis (MS), R&D, Small Molecules
MediciNova received positive Optical Coherence Tomography (OCT) results from the company's SPRINT-MS Phase IIb trial of MN-166 (ibudilast) in multiple sclerosis subjects.
November 25, 2020 /by BioSpace
https://www.pharmalive.com/wp-content/uploads/2020/11/MediciNovas-Ibudilast-Reduces-Retinal-Thinning-in-MS-Trial-Subjects-BioSpace-11-25-20.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2020-11-25 12:08:412020-11-30 15:44:46MediciNova's Ibudilast Reduces Retinal Thinning in MS Trial Subjects
MedDay's MS Therapy Fails in Phase III Trial
Clinical Trials, Progressive Multiple Sclerosis (MS), R&D
France-based MedDay Pharmaceuticals announced the company's MED1003 failed to meet the primary and secondary endpoints in the second pivotal Phase III trial for progressive multiple sclerosis (MS).
https://www.pharmalive.com/wp-content/uploads/2020/03/MedDay-MS-Study-Failure-BioSpace-3-11-20.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2020-03-11 12:42:502020-03-16 00:36:17MedDay's MS Therapy Fails in Phase III Trial